Sublay Versus Intraperitoneal Onlay Mesh Repair in Large Ventral Hernias
Launched by AHMED KAHLAWY MAHROUS MOHAMED · Oct 12, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different surgical methods for repairing large ventral hernias, which are bulges that can occur in the abdominal wall. The researchers want to find out which method is more effective: a technique called modified sublay hernioplasty or another called intraperitoneal onlay mesh repair. The main goal is to see how many patients experience a recurrence of their hernia within a year after surgery. They will also look at other important factors, such as complications during surgery, infection rates, pain levels after surgery, and how long patients stay in the hospital.
To participate in this trial, individuals need to be between 18 and 70 years old and generally fit for surgery. They should have a large, uncomplicated ventral hernia. However, individuals who have serious health issues that prevent them from safely undergoing anesthesia, those with complicated hernias, or those who are pregnant cannot participate. The trial is not yet recruiting participants, but it aims to provide valuable information to improve hernia repair techniques in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age (18-70) years, both sexes.
- • Fitness for surgery.
- • Patients with uncomplicated ventral hernia.
- • Large anterior abdominal wall defect.
- Exclusion Criteria:
- • Patients don't fit for general anesthesia due to sever co-morbidity.
- • Patients with complicated ventral hernia.
- • Patient refusal of surgical intervention.
- • History of bleeding disorders.
- • Pregnancy in female patients
About Ahmed Kahlawy Mahrous Mohamed
Ahmed Kahlawy Mahrous Mohamed is a dedicated clinical trial sponsor with a focus on advancing medical research and innovation. With a commitment to ethical practices and rigorous scientific methodologies, he oversees the design, implementation, and management of clinical trials aimed at evaluating new therapeutic interventions. His expertise spans various therapeutic areas, ensuring compliance with regulatory standards and fostering collaborations with healthcare professionals and research institutions. Driven by a passion for improving patient outcomes, Ahmed strives to contribute to the development of safe and effective treatments through well-structured clinical studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported